Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells.

about

An Interplay between Senescence, Apoptosis and Autophagy in Glioblastoma Multiforme-Role in Pathogenesis and Therapeutic Perspective.

P2860

Q52644558-EFC7F77E-47D7-4221-9689-010230838B79

P2860

Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells.

Item

http://www.wikidata.org/entity/Q47114557

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells.

@en

Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells.

@nl

type

Item

label

Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells.

@en

Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells.

@nl

prefLabel

Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells.

@en

Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells.

@nl

P1476

Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells

@en

P2093

Diana Cardoso-Carneiro

http://www.w3.org/2001/XMLSchema#string

Fernanda Paula Cury

http://www.w3.org/2001/XMLSchema#string

Inês Valbom

http://www.w3.org/2001/XMLSchema#string

Viviane Aline Silva

http://www.w3.org/2001/XMLSchema#string

P2860

Modes of resistance to anti-angiogenic therapy

Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme

Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H(+) symporters

The epidemiology of glioma in adults: a "state of the science" review

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody.

P304

103657-103670

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.21761

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Vera Miranda-Gonçalves

P577

2017-10-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29262591

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

5732757

http://www.w3.org/2001/XMLSchema#string

Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells.

about

P2860

P2860

Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932